Ypsomed Holding AG (LON:0QLQ)
London
· Delayed Price · Currency is GBP · Price in CHF 405.83
+17.33 (4.46%)
At close: May 30, 2025
Ypsomed Holding AG Revenue
In the fiscal year ending March 31, 2025, Ypsomed Holding AG had annual revenue of 748.87M CHF with 36.54% growth. Ypsomed Holding AG had revenue of 324.01M in the half year ending September 30, 2024, with 32.66% growth.
Revenue
748.87M CHF
Revenue Growth
+36.54%
P/S Ratio
7.62
Revenue / Employee
283.23K CHF
Employees
2,644
Market Cap
5.00B GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 748.87M | 200.41M | 36.54% |
| Mar 31, 2024 | 548.46M | 51.00M | 10.25% |
| Mar 31, 2023 | 497.46M | 32.62M | 7.02% |
| Mar 31, 2022 | 464.84M | 61.19M | 15.16% |
| Mar 31, 2021 | 403.66M | 9.39M | 2.38% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| GSK plc | 31.53B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |